NEW YORK (GenomeWeb) – Israeli RNAi drug developer Silenseed has filed to go public in the US, looking to raise around $36.4 million to support the continued clinical development of its oncology pipeline and the implantable delivery system that enables it.

According to Silenseed CEO and Co-founder Amotz Shemi, the company had been exploring opportunities to raise the money needed to conduct the clinical testing of its flagship pancreatic cancer treatment, which recently completed a Phase I study, eventually deciding to pursue an initial public offering on the Nasdaq.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.